Fc-fusion Cell Line Development: Expression and Analytical Strategies

Following the clinical and commercial success of monoclonal antibodies, Fc-based therapies have captured substantial attention in the biopharmaceutical industry; however, their inherent complexity continues to present manufacturability challenges in both upstream and downstream processes. We describe high titer expression of Fc-fusion proteins using FUJIFILM Diosynth Biotechnologies’ Apollo™ X platform coupled with integrated quality assessments, enhancing our support for clients through the predicted growth in Fc-fusion clinical applications.